

ASX ANNOUNCEMENT

30 April, 2025

Activated Probiotics New Product Launches

- Biome to release two new Products into the Activated Probiotics range in Q4 FY25
- Biome Her™ Pessary
 - Featuring a clinically-trialled combination of probiotic strains shown to support healthy vaginal microbiome balance¹
- Biome Perinatal™ Probiotic
 - Featuring a clinically-trialled probiotic strain shown to support healthy pregnancy outcomes and improve postpartum mood balance²⁻⁵

Microbiome health company **Biome Australia Limited** (ASX: BIO) ('Biome' or 'the company') is pleased to provide an update on two new product launches supporting women's health through our flagship brand, Activated Probiotics.

Women's health is the number one vitamin and dietary supplements category by sales volume in Australia⁶. With over 75% of Australian households using complementary medicines⁶, demand for female-focused products– including those targeting vaginal health, fertility, pregnancy, and overall well-being– continues to rise. Female customers and patients are the leading demographic of complementary medicine consumers, often being the main purchaser of probiotics and complementary medicines. With two new product offerings, Biome is aiming to better support this demographic at earlier life stages and through their child-bearing years.

Biome Her™ Pessary

Biome Her™ Pessary will complement Biome Her™ Probiotic, an oral probiotic for vaginal microbiome balance, by providing targeted support through a new vaginally-inserted probiotic pessary. This product includes clinically-trialled probiotic strains¹ and will include 10 vaginal capsules designed to be recommended for short-term use to women with acute vaginal health concerns, and has been listed on the Australian Register of Therapeutic Goods to maintain/support vaginal healthy flora/microflora.

Biome Perinatal™ Probiotic

Biome has also identified an opportunity in the Australian and international markets for a high-quality evidence-based probiotic for use before, during and after pregnancy including throughout breastfeeding.

Biome Perinatal+ Probiotic, Biome's upcoming offering in this category, includes clinically-trialled probiotic strains which have demonstrated clinical evidence of efficacy for their ability to support the health needs of women before, during and after pregnancy²⁻⁵, and has been listed on the Australian Register of Therapeutic Goods with the following health claims:

- Maintain/support healthy pregnancy
- Helps enhance/promote maternal health
- Helps enhance/promote maternal postnatal health
- Support healthy emotional/mood balance in post-partum women

Alongside women's products being number one in the industry, there were \$98.6 million prenatal multivitamin supplement sales in 2024, a key co-prescribing opportunity for Biome Perinatal™ Probiotic.⁶

Lactobacillus acidophilus LA02 and Lactobacillus fermentum LF10

Biome has worked with its research partners to identify key probiotic strains that have been found in human clinical trials to support vaginal microbiota balance. In women with recurrent vaginal thrush, *Lactobacillus acidophilus* LA02 and

Lactobacillus fermentum LF10 have been found to reduce relapse rates to 27.6% when administered after standard treatment¹. Current standard treatment approaches alone are not particularly effective, with post-treatment relapse rates as high as 57%⁷.

Lactobacillus rhamnosus HN001

Similarly, probiotic strains which help to improve health outcomes during pregnancy and into motherhood have also been an area of focus. *Lactobacillus rhamnosus* HN001 is one such strain that was identified as a well-researched probiotic intervention indicated for this application, with reductions in the rate of gestational diabetes⁵, improved postpartum mood balance², and protection against eczema development⁴ in future children* observed when supplemented during pregnancy and throughout breastfeeding (*when the children were also supplemented with this probiotic strain in the first two years of life).


References

1. Murina F, Graziottin A, Vicariotto F, De Seta F. Can *Lactobacillus fermentum* LF10 and *Lactobacillus acidophilus* LA02 in a slow-release vaginal product be useful for prevention of recurrent vulvovaginal candidiasis?: A clinical study. *J Clin Gastroenterol*. 2014;48(December):S102–5.
2. Slykerman, R. F., Hood, F., Wickens, K., Thompson, J. M. D., Barthow, C., Murphy, R., ... & Mitchell, E. A. (2017). Effect of *Lactobacillus rhamnosus* HN001 in pregnancy on postpartum symptoms of depression and anxiety: a randomised double-blind placebo-controlled trial. *EBioMedicine*, 24, 159-165.
3. Kalliomäki, M., Salminen, S., Poussa, T, et al. (2007) Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomised, placebo-controlled trial. *J Allergy Clin Immunol* 119, 1019–1021.
4. Wickens, K., Black, P. N., Stanley, T. V., Mitchell, E., Fitzharris, P., Tannock, G. W., ... & Probiotic Study Group. (2008). A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. *Journal of Allergy and Clinical Immunology*, 122(4), 788-794.
5. Wickens, K. L., Barthow, C. A., Murphy, R., Abels, P. R., Maude, R. M., Stone, P. R., ... & Crane, J. (2017). Early pregnancy probiotic supplementation with *Lactobacillus rhamnosus* HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. *British Journal of Nutrition*, 117(6), 804-813.
6. Complementary Medicines Australia. (2024). 2024 Industry Snapshot. Available from: <https://cmaustralia.org.au/wp-content/uploads/CMA-Snapshot-2024.pdf>
7. Bradfield Strydom M, Walpola RL, Khan S, Ware RS, Tiralongo E. Evidence-based update on Australasian pharmaceutical prescribing approaches for recurrent vulvovaginal candidiasis. *Aust N Z J Obstet Gynaecol*. 2021 Aug;61(4):496-499.

Women's Health


Biome Her™ Pessary





A new vaginal pessary to support women re-establish a healthy vaginal microbiome

Biome Her™ Pessary is more suitable for short-term use for women with acute vaginal health concerns, and includes clinically trialled probiotic strains that help women re-establish and maintain a healthy vaginal microbiome.




Practitioner-only product

Biome Her™ Pessary

- To help maintain a healthy vaginal microbiome

Formulation

<i>Lactobacillus crispatus</i> LCR01 (DSM 24619)	1 BLB*
<i>Lactobacillus fermentum</i> LF10 (DSM 19187)	1 BLB*
<i>Lactobacillus acidophilus</i> LA02 (DSM 21717)	1 BLB*
Total live bacteria	3 BLB*



Women's health is the
#1 dietary supplements
category by sales volume
in Australia²

Biome Her™ Pessary

Market analysis


The global women's probiotic market is growing at a compound annual growth rate (CAGR) of 18.1% from 2024 to 2034.

The women's probiotic market in Australia and New Zealand is projected to grow at a CAGR of 8.2% from 2024 to 2034.¹

With over 75% of Australian households using complementary medicines, demand for female-focused products—including those targeting vaginal, fertility and pregnancy—continues to rise.²

1. Future Market Insights. (2024). Women's Probiotic Market Report. Retrieved from <https://www.futuremarketinsights.com/reports/women-probiotic-market>

2. Complementary Medicines Australia. (2024). CMA Snapshot 2024. Retrieved from <https://cmaustralia.org.au/wp-content/uploads/CMA-Snapshot-2024.pdf>



Biome Her™ Pessary

Consumer needs

Approximately 70% of women will develop vaginal thrush in their lifetime

Recurrent vaginal thrush affects up to **10% of Australian women**¹

It has debilitating effects on the physical and emotional well-being of these women¹

Standard treatment is not particularly effective with post-treatment **relapse rates as high as 57%**¹


1. Bradfield Strydom M, Walpole RL, Khan S, Ware RS, Tiralongo E. Evidence-based update on Australasian pharmaceutical prescribing approaches for recurrent vulvovaginal candidiasis. Aust N Z J Obstet Gynaecol. 2021 Aug;61(4):496-499.

2. Murina F, Graziottin A, Vicariotto F, De Seta F. Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a slow-release vaginal product be useful for prevention of recurrent vulvovaginal candidiasis?: A clinical study. J Clin Gastroenterol. 2014;48(December):S102-5.

Women's Health

Biome Perinatal™ Probiotic






Practitioner-only product

Biome Perinatal™ Probiotic

- Supports a healthy pregnancy
- Helps promote maternal health
- Supports healthy postpartum mood balance

Formulation

<i>Lactobacillus rhamnosus</i> GG (ATCC 53103)	5 BLB*
<i>Lactobacillus rhamnosus</i> HN001 (ATCC SD5675)	6 BLB*
<i>Lactobacillus crispatus</i> LCR01 (DSM 24619)	1 BLB*
<i>Bifidobacterium breve</i> BR03 (DSM 16604)	5 BLB*
<i>Bifidobacterium animalis subsp. lactis</i> BA05 (DSM 18352)	3 BLB*
Total live bacteria (BLB=Billion Live Bacteria)	20 BLB*



A new probiotic formulation to support women before, during and after their pregnancy journey

Biome Perinatal™ is formulated with clinically-trialled probiotic strains that have evidence to support a healthy pregnancy, promote maternal health and support healthy postpartum mood balance.



Biome Perinatal™ Probiotic

Market analysis

According to the Australian Institute of Health and Welfare, there were nearly 300,000 pregnant women in Australia in 2022¹. Biome Perinatal™ offers targeted probiotic support to this group of women prior to, during and in the one year period following their pregnancy journey, compounding into a total market size of approximately 1 million+.

Biome Perinatal™ offers a streamlined co-prescribing opportunity for the highly engaged customer purchasing prenatal supplements.

1. Australian Institute of Health and Welfare. (2024). Australia's mothers and babies: State and territory. Retrieved from <https://www.aihw.gov.au/reports/mothers-babies/australias-mothers-babies/contents/overview-and-demographics/state-and-territory>

2. Complementary Medicines Australia. (2024). CMA Snapshot 2024. Retrieved from <https://cmaustralia.org.au/wp-content/uploads/CMA-Snapshot-2024.pdf>

–ENDS–

Approved for release by the Biome Australia board of directors.

Investor Hub

Biome has launched a new interactive investor hub. To view a video presentation of this announcement, ask questions or sign up for future company updates, please visit the investor hub via [this link](https://investorhub.biomeaustralia.com/) (https://investorhub.biomeaustralia.com/).

About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics[®].

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

Biome also develops, licenses and distributes a scientifically formulated, organic nutraceutical range, Activated Nutrients[®].

For more information visit: www.biomeaustralia.com

Investor Relations

Rechelle Friend

corporate@biomeaustralia.com

(03) 9017 5800

Forward looking statements

*This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (**Forward Looking Statements**).*

Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Any Forward Looking Statements containing forward looking financial information provided in this release is for illustrative purposes only and is not represented as being indicative of Biome's views on its future financial condition and/or performance.

Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or results expressed or implied in any Forward Looking Statements) contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.

Investors are strongly cautioned not to place undue reliance on Forward Looking Statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the Covid-19 pandemic.
